Recruitment

Recruitment Status
Completed
Estimated Enrollment
94

Inclusion Criterias

Ocular hypertension or glaucoma that requires treatment with medication
Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Ocular hypertension or glaucoma that requires treatment with medication
Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

Exclusion Criterias

History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study

Summary

Conditions
  • Glaucoma
  • Ocular Hypertension
Type
Interventional
Phase
Phase 4
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Single (Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criterias

Ocular hypertension or glaucoma that requires treatment with medication
Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes
Ocular hypertension or glaucoma that requires treatment with medication
Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

Exclusion Criterias

History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study

Locations

Racine, Wisconsin
Racine, Wisconsin

Tracking Information

NCT #
NCT02097719
Collaborators
Not Provided
Investigators
Study Director: Medical Director Allergan